Samyn N, van Haeren C
National Instituut voor Criminalistiek en Criminologie, Brussels, Belgium.
Int J Legal Med. 2000;113(3):150-4. doi: 10.1007/s004140050287.
Potential drug users participated voluntarily in a Belgian study on the usefulness of the non-instrumental immunoassay Drugwipe (Securetec, Germany) for the screening of cocaine, opiates, amphetamine and cannabinoids in saliva and sweat. If one of the screening assays (urine, oral fluid, sweat) showed a positive result, blood and saliva were collected. The on-site Drugwipe results were correlated with the Drugwipe results for saliva in the laboratory and with the GC/MS results of the corresponding saliva, plasma and urine samples and pharmacological effects at the time of sampling. The Drugwipe assay proved to be sufficiently sensitive for the detection of recent cocaine (n = 6) and amphetamine (n = 15) abuse, whether the device was wiped on the tongue or on the surface of the body, or when a saliva sample was applied to the wiping part. In five of the six potential cocaine users, the saliva concentrations of cocaine exceeded 1,000 ng/ml. In the amphetamine group, the saliva concentrations of amphetamine, MDMA or both were high (> 1,000 ng/ml) in 13 subjects. For cocaine and amphetamine, the positive scores for Drugwipe matched the GC/MS results for the three body fluids. Recent heroin abuse (n = 5) could be demonstrated to some extent with Drugwipe on samples from the tongue but only the two subjects with the highest saliva concentrations of MAM (> 500 ng/ml) and morphine (> 500 ng/ml) were positive. If the legal cut-off value for driving under the influence of opiates in Belgium (20 ng/ml of free morphine in plasma) was taken into account, only three subjects would have been legally positive. For cannabinoids (n = 15), false negatives and even some false positives were observed. Saliva can be considered as a useful analytical matrix for the detection of drugs of abuse after recent abuse when analysed with GC/MS.
潜在吸毒者自愿参与了一项比利时的研究,该研究旨在探讨非仪器免疫分析法Drugwipe(德国Securetec公司生产)用于筛查唾液和汗液中可卡因、阿片类药物、苯丙胺和大麻素的有效性。如果其中一项筛查检测(尿液、口腔液、汗液)呈阳性结果,则采集血液和唾液样本。现场Drugwipe检测结果与实验室中唾液的Drugwipe检测结果、相应唾液、血浆和尿液样本的气相色谱/质谱(GC/MS)检测结果以及采样时的药理效应进行了关联。结果表明,无论该检测设备是擦拭在舌头还是身体表面,亦或是将唾液样本涂抹在擦拭部位,Drugwipe检测法对于检测近期可卡因(n = 6)和苯丙胺(n = 15)滥用都具有足够的敏感性。在六名潜在可卡因使用者中,有五人的唾液中可卡因浓度超过1000 ng/ml。在苯丙胺组中,13名受试者的唾液中苯丙胺、摇头丸或两者的浓度都很高(> 1000 ng/ml)。对于可卡因和苯丙胺,Drugwipe的阳性评分与三种体液的GC/MS检测结果相符。在一定程度上,通过对来自舌头的样本进行Drugwipe检测可以证明近期海洛因滥用(n = 5)的情况,但只有唾液中去甲吗啡(> 500 ng/ml)和吗啡(> 500 ng/ml)浓度最高的两名受试者呈阳性。如果考虑比利时关于在阿片类药物影响下驾驶的法定临界值(血浆中游离吗啡20 ng/ml),那么只有三名受试者会在法律上被判定为阳性。对于大麻素(n = 15),观察到了假阴性甚至一些假阳性结果。当使用GC/MS进行分析时,唾液可被视为检测近期滥用药物的一种有用分析基质。